Pain Relief Marketing And Refranchising Will Transform This Chiropractic Network Over The Next Decade

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

06 Jan 26

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Decreased 14%

JYNT: Share Repurchases And New Corporate Partnership Will Support Stronger Outlook

Joint doubles down on returning cash to shareholders and adds a new employer partnership that could help bring more patients into local clinics. With the company sticking to its outlook for next year, the key question is whether these moves can offset uneven clinic sales and support better results over time.

1 view

Fair Value vs Share Price

US$12

vs US$8.2531.3% undervalued

7.2%

Revenue growth

32.7%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Joint

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet and good value.

Market capUS$112.0m

PB7.1x

Estimated Growth4.7%

Dividend YieldN/A

Full analysis

CEO & management

Sanjiv Razdan

CEO

1.4yrs

CEO Tenure

Operates and is a franchisor and operator of chiropractic clinics in the United States.